Related Experiment Videos
[Treatment of moderate hypertension: monotherapy or combination?]
1Service de Médecine Interne, Hôpital Avicenne, Bobigny.
Insights
Strict blood pressure control is vital for preventing cardiovascular disease. Combining hypertension medications offers better control and tolerability than monotherapy, especially for younger patients.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Hypertension management requires early and strict blood pressure control for long-term cardiovascular benefits.
- Monotherapy may not be sufficient for all patients, particularly younger individuals with mild hypertension, due to potential metabolic side effects.
Purpose:
- To evaluate the efficacy and tolerability of combination therapy versus monotherapy in hypertension management.
- To explore strategies for optimizing blood pressure normalization and minimizing metabolic disturbances.
Summary:
- Combination therapy for hypertension can achieve blood pressure control in 80-90% of cases with improved patient compliance.
- Using lower doses in combination therapy may reduce interference with metabolic, endocrine, and vascular functions compared to monotherapy.
Impact:
- Combination therapy offers a promising approach to enhance hypertension treatment outcomes and long-term prognosis.
- This strategy supports personalized treatment by addressing both blood pressure control and metabolic health.
Abstract:
The treatment of hypertension must fall within a strategy of the early and strict control of blood pressure levels. Only actual normalisation of blood pressure can offer long term benefit regarding the incidence of cardiovascular morbidity and mortality. While major studies undertaken up to now have already proven the benefit of treatment using classical drugs as monotherapy, it is now necessary to offer all young hypertension patients, even mild, with strict control of levels, a non-pharmacological action on risk factors, and a choice of treatments ensuring no loss of part of the prognostic benefit as a result of persistence or worsening or sub-clinical metabolic disorders. It seems logical, when first-line monotherapy is selected from among the five major drug groups recommended, is neither perfectly effective nor perfectly tolerated, and risks worsening a metabolic disorder in the long term, to use a combination of hypotensive drugs. This should enable blood pressure control in 80 to 90% of cases, and improved acceptability, a major factor in treatment compliance. It is reasonable to hope, in the long term, that the use of a combination of lower doses than as monotherapy, will ensure less interference with major metabolic, endocrine and vascular functions, leading to a further improvement in the prognosis of treated hypertension.